0000000000075704

AUTHOR

Ivan Gentile

showing 10 related works from this author

Ceftazidime-avibactam use for klebsiella pneumoniae carbapenemase-producing k. pneumoniae infections: A retrospective observational multicenter study

2021

Abstract Background A growing body of observational evidence supports the value of ceftazidime-avibactam (CAZ-AVI) in managing infections caused by carbapenem-resistant Enterobacteriaceae. Methods We retrospectively analyzed observational data on use and outcomes of CAZ-AVI therapy for infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae (KPC-Kp) strains. Multivariate regression analysis was used to identify variables independently associated with 30-day mortality. Results were adjusted for propensity score for receipt of CAZ-AVI combination regimens versus CAZ-AVI monotherapy. Results The cohort comprised 577 adults with bloodstream infections (n = 391) or nonba…

Microbiology (medical)Adultmedicine.medical_specialtyAzabicyclo CompoundcarbapenemasesBacterial ProteinMicrobial Sensitivity TestsNeutropeniaCeftazidimebeta-Lactamasesbeta-LactamaseCarbapenemasecarbapenemaseBacterial ProteinsRetrospective StudieLower respiratory tract infectionInternal medicineDrug CombinationAnti-Bacterial AgentmedicineHumansKPC-producing Klebsiella pneumoniaeRetrospective StudiesSeptic shockbusiness.industryCeftazidime-avibactamMicrobial Sensitivity Testceftazidime-avibactamMortality rateCarbapenemases; Ceftazidime-avibactam; KPC-producing Klebsiella pneumoniae; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Drug Combinations; Humans; Microbial Sensitivity Tests; Retrospective Studies; beta-Lactamases; Klebsiella Infections; Klebsiella pneumoniaeKPC-producing Klebsiella pneumoniae; carbapenemases; ceftazidime-avibactammedicine.diseaseCeftazidime/avibactamSettore MED/17KPC-producing Klebsiella pneumoniae; carbapenemases; ceftazidime-avibactam; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Drug Combinations; Humans; Microbial Sensitivity Tests; Retrospective Studies; beta-Lactamases; Klebsiella Infections; Klebsiella pneumoniaeAnti-Bacterial AgentsKlebsiella InfectionsDrug CombinationsKlebsiella pneumoniaeInfectious DiseasesCohortPropensity score matchingObservational studybusinessAzabicyclo Compoundsmedicine.drugHumanKlebsiella Infection
researchProduct

Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicentre Italian CORIST Study

2021

Abstract Introduction A hypercoagulable condition was described in patients with coronavirus disease 2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing to disease progression and lethality. Aim We evaluated if in-hospital administration of heparin improved survival in a large cohort of Italian COVID-19 patients. Methods In a retrospective observational study, 2,574 unselected patients hospitalized in 30 clinical centers in Italy from February 19, 2020 to June 5, 2020 with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 infection were analyzed. The primary endpoint in a time-to event analysis was in-hospital death, comparing patients who receive…

Malemedicine.medical_specialtySettore MED/17 - Malattie Infettivecoronavirusheparin030204 cardiovascular system & hematologyLower risklaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineClinical endpointmedicineHumansThrombophilia030212 general & internal medicineHospital MortalityBlood CoagulationSurvival analysisAgedRetrospective Studiestreatmentbusiness.industryHeparinMortality rateCOVID-19mortalityLow-Molecular-WeightAnticoagulantsCOVID-19Retrospective cohort studyHeparinHematologyHeparin Low-Molecular-WeightMiddle AgedmortalitySurvival AnalysisCOVID-19 Drug Treatmentcoagulation activationcoronaviruItalytreatmentsPropensity score matchingcoagulation activation; coronavirus; COVID-19; heparin; mortality; treatmentsFemalecoagulation activation; coronavirus; COVID-19; heparin; mortality; treatments; Aged; Anticoagulants; Blood Coagulation; COVID-19; Female; Heparin; Heparin Low-Molecular-Weight; Hospital Mortality; Humans; Italy; Male; Middle Aged; Retrospective Studies; Survival Analysis; Thrombophiliabusinessmedicine.drug
researchProduct

Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

2023

Background and aims: Severe liver disease markers assessed before HCV eradication are acknowledged to usually improve after the SVR. We prospectively evaluated, in the PITER cohort, the long-term HCC risk profile based on predictors monitored after HCV eradication by direct-acting antivirals in patients with cirrhosis. Methods: HCC occurrence was evaluated by Kaplan-Meier analysis. Cox regression analysis identified the post-treatment variables associated with de-novo HCC; their predictive power was presented in a nomogram. Results: After the end of therapy (median follow-up:28.47 months), among 2064 SVR patients, 119 (5.8%) developed de-novo HCC. The HCC incidence was 1.90%, 4.21%, 6.47% a…

Settore MED/12Real-life cohort.HepatologyDirect-acting antiviral; HCC; Long term outcomes; Predictive factors; Real-life cohortGastroenterologyReal-life cohortLong term outcomeHCCPredictive factorDirect-acting antiviralLong term outcomesPredictive factors
researchProduct

Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian…

2020

Abstract Background Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19. Objective We set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and COVID-19 in-hospital mortality. Methods In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were analyzed. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received HCQ with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatme…

Malemedicine.medical_specialty030204 cardiovascular system & hematologyLower risklaw.inventionCOVID-19; Disease severity; Hydroxychloroquine; Inflammation; Mortality; Aged; Aged 80 and over; COVID-19; Female; Hospital Mortality; Humans; Hydroxychloroquine; Italy; Male; Middle Aged; Retrospective Studies; Treatment OutcomeCOVID-19; Disease severity; Hydroxychloroquine; Inflammation; Mortality03 medical and health sciences0302 clinical medicineRandomized controlled trialRetrospective StudielawInternal medicine80 and overInternal MedicinemedicineHumans030212 general & internal medicineHospital MortalityMortalityRisk factorDisease severityAgedRetrospective StudiesInflammationAged 80 and overbusiness.industryMortality rateCOVID-19HydroxychloroquineRetrospective cohort studyMiddle AgedCOVID-19 Drug TreatmentTreatment OutcomeItalyPropensity score matchingCommentaryObservational studyFemalebusinessHumanmedicine.drugHydroxychloroquineEuropean journal of internal medicine
researchProduct

RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis…

2020

Abstract Objective The hypothesis that been set forward that use of Renin Angiotensin Aldosterone System (RAAS) inhibitors is associated with COVID−19 severity. We set-up a multicenter Italian collaboration (CORIST Project, ClinicalTrials.gov ID: NCT04318418 ) to retrospectively investigate the relationship between RAAS inhibitors and COVID−19 in-hospital mortality. We also carried out an updated meta-analysis on the relevant studies. Methods We analyzed 4069 unselected patients with laboratory-confirmed SARS-CoV-2 infection and hospitalized in 34 clinical centers in Italy from February 19, 2020 to May 23, 2020. The primary end-point in a time-to event analysis was in-hospital death, compar…

0301 basic medicineMalePhysiologyMiddle Aged Renin-Angiotensin SystemAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyACE-I; ARB; COVID-19; angiotensin converting enzyme inhibitors; angiotensin receptor blockers; mortality; sartansSeverity of Illness IndexRenin-Angiotensin System0302 clinical medicineangiotensin converting enzyme inhibitorsRisk FactorsACE-I80 and overMedicineHospital MortalitySartanAged 80 and overIncidence (epidemiology)IncidenceHazard ratioAngiotensin Receptor AntagonistMiddle AgedsartansARBHospitalizationAntihypertensive AgentItalyMeta-analysisHypertensionSartansMolecular MedicineFemaleRisk assessmentHumanmedicine.medical_specialtyAngiotensin converting enzyme inhibitors; ACE-I; Angiotensin receptor blockers; ARB; Sartans; COVID-19; MortalityCoronavirus disease 2019 (COVID-19)Risk AssessmentArticleCOVID−1903 medical and health sciencesAngiotensin Receptor AntagonistsMeta-Analysis as TopicInternal medicineSeverity of illnessHumansAngiotensin receptor blockerMortalityAntihypertensive AgentsAgedPharmacologyACE-I; ARB; Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; COVID−19; Mortality; Sartans; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; COVID-19; Female; Hospitalization; Humans; Hypertension; Incidence; Italy; Male; Meta-Analysis as Topic; Middle Aged; Renin-Angiotensin System; Risk Assessment; Risk Factors; Severity of Illness Index; Hospital Mortalitybusiness.industryRisk FactorCOVID-19Angiotensin-Converting Enzyme InhibitorAngiotensin receptor blockersmortalityConfidence intervalangiotensin receptor blockersAngiotensin converting enzyme inhibitors030104 developmental biologyACE-I; ARB; COVID-19 angiotensin converting enzyme inhibitors angiotensin receptor blockers mortality sartansObservational studyAngiotensin converting enzyme inhibitorbusiness
researchProduct

Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings f…

2020

Background and aims There is poor knowledge on characteristics, comorbidities and laboratory measures associated with risk for adverse outcomes and in-hospital mortality in European Countries. We aimed at identifying baseline characteristics predisposing COVID-19 patients to in-hospital death. Methods and results Retrospective observational study on 3894 patients with SARS-CoV-2 infection hospitalized from February 19th to May 23rd, 2020 and recruited in 30 clinical centres distributed throughout Italy. Machine learning (random forest)-based and Cox survival analysis. 61.7% of participants were men (median age 67 years), followed up for a median of 13 days. In-hospital mortality exhibited a…

MaleEpidemiologyEndocrinology Diabetes and MetabolismMedicine (miscellaneous)030204 cardiovascular system & hematologycomputer.software_genreMachine Learning0302 clinical medicineRetrospective StudieRisk FactorsCardiovascular DiseaseEpidemiology80 and overMedicineAge FactorViralHospital MortalityBetacoronavirus Hospital MortalityYoung adultAged 80 and overNutrition and DieteticsCOVID-19; Epidemiology; In-hospital mortality; Risk factorsMortality rateHazard ratioAge FactorsMiddle AgedIn-hospital mortalityC-Reactive ProteinCardiovascular DiseasesFemaleSurvival AnalysiCardiology and Cardiovascular MedicineCoronavirus InfectionsHumanGlomerular Filtration RateAdultmedicine.medical_specialtyAdolescentPneumonia Viral030209 endocrinology & metabolismSettore MED/17 - MALATTIE INFETTIVEMachine learningCOVID-19; Epidemiology; In-hospital mortality; Risk factors; Adolescent; Adult; Age Factors; Aged; Aged 80 and over; C-Reactive Protein; COVID-19; Cardiovascular Diseases; Coronavirus Infections; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Pandemics; Pneumonia Viral; Retrospective Studies; Risk Factors; SARS-CoV-2; Survival Analysis; Young Adult; Betacoronavirus; Hospital Mortality; Machine LearningArticle03 medical and health sciencesBetacoronavirusYoung AdultHumansRisk factorPandemicsSurvival analysisAgedRetrospective StudiesPandemicBetacoronavirubusiness.industryCoronavirus InfectionSARS-CoV-2Risk FactorCOVID-19Retrospective cohort studyPneumoniaSurvival AnalysisConfidence intervalRisk factorsArtificial intelligencebusinesscomputerNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Lopinavir/ritonavir and darunavir/cobicistat in hospitalized covid-19 patients: Findings from the multicenter italian corist study

2021

Background: Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients.Objectives: To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID-19 patients.Study Design: Multicenter observational study of COVID-19 patients admitted in 33 Italian hospitals. Medications, preexisting conditions, clinical measures, and outcomes were extracted from medical records. Patients were retrospectively divided in three groups, according to use of LPV/r, DRV/c or none of them. Primary outcome in a time-to event analysis was death. We used Cox proportional-hazards models with inverse probability of…

Medicine (General)medicine.medical_specialtyLopinavir/ritonavirLopinavirR5-920Internal medicinemedicineDarunavirOriginal ResearchCOVID-19; Darunavir; In-hospital mortality; Lopinavir; SARS-CoV-2DarunavirCOVID-19; SARS-CoV-2; darunavir; in-hospital mortality; lopinavirbusiness.industrySARS-CoV-2CobicistatMortality rateCOVID-19LopinavirGeneral Medicinemedicine.diseaseIn-hospital mortalityPropensity score matchingMedicineRitonavirbusinessmedicine.drugKidney disease
researchProduct

Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER …

2021

Background: Direct-acting antivirals are highly effective for the treatment of hepatitis C virus (HCV) infection, regardless race/ethnicity. We aimed to evaluate demographic, virological and clinical data of HCV-infected migrants vs. natives consecutively enrolled in the PITER cohort. Methods: Migrants were defined by country of birth and nationality that was different from Italy. Mann-Whitney U test, Chi-squared test and multiple logistic regression were used. Results: Of 10,669 enrolled patients, 301 (2.8%) were migrants: median age 47 vs. 62 years, (p < 0.001), females 56.5% vs. 45.3%, (p < 0.001), HBsAg positivity 3.8% vs. 1.4%, (p < 0.05). Genotype 1b was prevalent in both gro…

MaleHCV genotypesEthnic groupLinked-to-care patientComorbidityHepacivirusLogistic regressionmedicine.disease_causeComorbidities; Direct acting antivirals; HCV Cohort; Linked-to-care patients; Aged; Antiviral Agents; Coinfection; Comorbidity; Female; Hepacivirus; Hepatitis C Chronic; Humans; Italy; Male; Middle Aged; Transients and MigrantsComorbidities0302 clinical medicineMedicineComorbidities; Direct acting antivirals; HCV Cohort; Linked-to-care patientsChronicTransients and MigrantsCoinfectionGastroenterologyvirus diseasesMiddle AgedHepatitis CLife evaluationItaly030220 oncology & carcinogenesisLinked-to-care patientsCohort030211 gastroenterology & hepatologyFemaleComorbiditieHumanHepatitis C virusSettore MED/12 - GASTROENTEROLOGIAAntiviral AgentsDirect acting antivirals03 medical and health sciencesDisease severityHumansAgedAntiviral AgentHepaciviruHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAHepatitis C Chronicmedicine.diseaseComorbiditydigestive system diseasesDirect acting antiviralHCV CohortbusinessDemography
researchProduct

Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering

2021

The efficacy of hydroxychloroquine (HCQ) in treating SARS-CoV-2 infection is harshly debated, with observational and experimental studies reporting contrasting results. To clarify the role of HCQ in Covid-19 patients, we carried out a retrospective observational study of 4,396 unselected patients hospitalized for Covid-19 in Italy (February–May 2020). Patients’ characteristics were collected at entry, including age, sex, obesity, smoking status, blood parameters, history of diabetes, cancer, cardiovascular and chronic pulmonary diseases, and medications in use. These were used to identify subtypes of patients with similar characteristics through hierarchical clustering based on Gower distan…

MaleMedicine (General)Antimalarial030204 cardiovascular system & hematologySeverity of Illness IndexHospital Mortality.0302 clinical medicineRetrospective Studie80 and overCluster Analysis030212 general & internal medicineHospital MortalityAged; Aged 80 and over; Antimalarials; COVID-19; Cluster Analysis; Female; Humans; Hydroxychloroquine; Italy; Male; Middle Aged; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Hospital MortalityAged 80 and overMiddle AgedTreatment OutcomeItalyFemaleBiotechnologymedicine.drugResearch ArticleHydroxychloroquinemedicine.medical_specialtyArticle SubjectBiomedical EngineeringRenal functionHealth Informatics03 medical and health sciencesAntimalarialsR5-920Internal medicineDiabetes mellitusSeverity of illnessmedicineMedical technologyHumansR855-855.5AgedRetrospective StudiesCluster Analysibusiness.industrySARS-CoV-2CancerCOVID-19Retrospective cohort studyHydroxychloroquinemedicine.diseaseObesityCOVID-19 Drug TreatmentSurgeryObservational studybusinessJournal of Healthcare Engineering
researchProduct

More Severe COVID-19 in Patients With Active Cancer: Results of a Multicenter Cohort Study

2021

BackgroundThe aim of the study was to compare coronavirus disease 2019 (COVID-19) severity presentation between oncologic and non-oncologic patients and to evaluate the impact of cancer type and stage on COVID-19 course.MethodsWe performed a multicentre, retrospective study involving 13 COVID-19 Units in Campania region from February to May 2020. We defined as severe COVID-19 presentation the cases that required mechanical ventilation and/or admission to Intensive Care Units (ICU) and/or in case of death.ResultsWe enrolled 371 COVID-19 patients, of whom 34 (9.2%) had a history or a diagnosis of cancer (24 solid, 6 onco-hematological). Oncologic patients were older (p<0.001), had more…

0301 basic medicineCancer Researchmedicine.medical_specialtyMultivariate analysismedicine.medical_treatmentoncologic patientseverity diseaseactive cancerMalignancy03 medical and health sciences0302 clinical medicineIntensive careInternal medicinemedicineStage (cooking)RC254-282Original ResearchMechanical ventilationSARS-CoV-2business.industryCOVID-19Neoplasms. Tumors. Oncology. Including cancer and carcinogensCancerRetrospective cohort studymedicine.diseaseoncologic patients030104 developmental biologyOncology030220 oncology & carcinogenesisbusinessCohort studyFrontiers in Oncology
researchProduct